explore -WSS

explore

author：explore 2025-08-26 23:47:24 - browse：39

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： NIH fellows want a pay raise. Will that mean less money for grants?

focus

WSS

Living with Fabry disease, a condition that causes chronic pain

The Biogen Aduhelm mess could happen again

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Cano Health’s bankruptcy is a warning for Medicare Advantage

Petition to FDA: Get the lead out of consumer hair dyes

Lecanemab for Alzheimer's is coming. Is the health system ready?

focus

explore

hotspot

Psychedelics group wrestles with new pharma identity

California’s proposed $25 per hour health care minimum wage

23andMe had bad news about my health. I wish a person had delivered it

A protest over insulin prices is seen as a fight for life

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How the political right came to back psychedelics to treat trauma

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Iowa House, Senate pass 6

As demand for Covid shots wanes, Moderna seeks its next success

Padmanee Sharma of MD Anderson at center of lawsuit over credit

leisure time

The CDC's new social media misinformation war

Retired US general questions alleged Putin, Prigozhin meeting

Living with Fabry disease, a condition that causes chronic pain

Surgery pushed Ben Carson to fame

Problems with a popular proposal to regulate AI in health care

Cano Health’s bankruptcy is a warning for Medicare Advantage

knowledge

leisure time

focus

explore